Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy

Graefes Arch Clin Exp Ophthalmol. 2015 Jun;253(6):979-81. doi: 10.1007/s00417-014-2891-0. Epub 2014 Dec 31.

Authors

Geoffrey K Broadhead¹, Andrew Chang

Affiliation

¹ Sydney Retina Clinic & Day Surgery, Sydney, Australia.

PMID: 25547617
DOI: 10.1007/s00417-014-2891-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Angiogenesis Inhibitors / therapeutic use*
Central Serous Chorioretinopathy / complications
Central Serous Chorioretinopathy / drug therapy*
Central Serous Chorioretinopathy / physiopathology
Choroidal Neovascularization / drug therapy*
Choroidal Neovascularization / etiology
Choroidal Neovascularization / physiopathology
Coloring Agents
Fluorescein Angiography
Humans
Indocyanine Green
Intravitreal Injections
Male
Middle Aged
Receptors, Vascular Endothelial Growth Factor / therapeutic use*
Recombinant Fusion Proteins / therapeutic use*
Subretinal Fluid
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology

Substances

Angiogenesis Inhibitors
Coloring Agents
Recombinant Fusion Proteins
VEGFA protein, human
Vascular Endothelial Growth Factor A
aflibercept
Receptors, Vascular Endothelial Growth Factor
Indocyanine Green